{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:29:17Z","timestamp":1790357357534,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T00:00:00Z","timestamp":1555545600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T00:00:00Z","timestamp":1555545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["UM1 CA164920"],"award-info":[{"award-number":["UM1 CA164920"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"crossref","award":["809195, 1100868"],"award-info":[{"award-number":["809195, 1100868"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["454508, 288704, 145684"],"award-info":[{"award-number":["454508, 288704, 145684"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Institute of Health","award":["1RO1CA159868"],"award-info":[{"award-number":["1RO1CA159868"]}]},{"name":"National Institutes of Health, National Cancer Institute, Cancer Epidemiology Training Grant","award":["T32-CA009529"],"award-info":[{"award-number":["T32-CA009529"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13058-019-1135-y","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T09:07:39Z","timestamp":1555578459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study"],"prefix":"10.1186","volume":"21","author":[{"name":"kConFab Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca D.","family":"Kehm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Hopper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther M.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly-Anne","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"MacInnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian S.","family":"Dite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger L.","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Zeinomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa C.","family":"Southey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Vahdat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Kornhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Cigler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy K.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham G.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue-Anne","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prue C.","family":"Weideman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gord","family":"Glendon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Nesci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene L.","family":"Andrulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saundra S.","family":"Buys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary B.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Terry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,18]]},"reference":[{"issue":"9291","key":"1135_CR1","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(01)06524-2","volume":"358","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2001","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358(9291):1389\u201399.","journal-title":"Lancet."},{"issue":"23","key":"1135_CR2","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316.","journal-title":"JAMA."},{"issue":"5","key":"1135_CR3","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1503523","volume":"374","author":"LC Hartmann","year":"2016","unstructured":"Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. N Engl J Med. 2016;374(5):454\u201368.","journal-title":"N Engl J Med"},{"issue":"9880","key":"1135_CR4","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","volume":"381","author":"J Cuzick","year":"2013","unstructured":"Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827\u201334.","journal-title":"Lancet."},{"issue":"25","key":"1135_CR5","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","volume":"364","author":"PE Goss","year":"2011","unstructured":"Goss PE, Ingle JN, Al\u00e9s-Mart\u00ednez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381\u201391.","journal-title":"N Engl J Med"},{"issue":"9922","key":"1135_CR6","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","volume":"383","author":"J Cuzick","year":"2014","unstructured":"Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383(9922):1041\u20138.","journal-title":"Lancet."},{"issue":"1","key":"1135_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13053-017-0075-8","volume":"15","author":"B Meiser","year":"2017","unstructured":"Meiser B, Wong W, Peate M, Julian-Reynier C, Kirk J, Mitchell G. Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review. Hered Cancer Clin Pract. 2017;15(1):14.","journal-title":"Hered Cancer Clin Pract"},{"issue":"4","key":"1135_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/annonc\/mdv590","volume":"27","author":"SG Smith","year":"2016","unstructured":"Smith SG, Sestak I, Forster A, et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol. 2016;27(4):575\u201390.","journal-title":"Ann Oncol"},{"issue":"1","key":"1135_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1897-4287-7-9","volume":"7","author":"LA Keogh","year":"2009","unstructured":"Keogh LA, Hopper JL, Rosenthal D, Phillips K-A. Australian clinicians and chemoprevention for women at high familial risk for breast cancer. Hered Cancer Clin Pract. 2009;7(1):9.","journal-title":"Hered Cancer Clin Pract"},{"issue":"1","key":"1135_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/1940-6207.CAPR-17-0162","volume":"11","author":"S Noonan","year":"2018","unstructured":"Noonan S, Pasa A, Fontana V, et al. A survey among breast cancer specialists on the low uptake of therapeutic prevention with tamoxifen or raloxifene. Cancer Prev Res (Phila). 2018;11(1):38\u201343.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"659","key":"1135_CR11","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.3399\/bjgp17X689377","volume":"67","author":"SG Smith","year":"2017","unstructured":"Smith SG, Foy R, McGowan JA, et al. Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs\u2019 attitudes. Br J Gen Pract. 2017;67(659):e414\u201327.","journal-title":"Br J Gen Pract"},{"issue":"9","key":"1135_CR12","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1002\/ijc.23340","volume":"122","author":"KA Metcalfe","year":"2008","unstructured":"Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008;122(9):2017\u201322.","journal-title":"Int J Cancer"},{"issue":"1","key":"1135_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.mayocp.2015.10.018","volume":"91","author":"A Bardia","year":"2016","unstructured":"Bardia A, Keenan TE, Ebbert JO, et al. Personalizing aspirin use for targeted breast cancer chemoprevention in postmenopausal women. Mayo Clin Proc. 2016;91(1):71\u201380.","journal-title":"Mayo Clin Proc"},{"issue":"8039","key":"1135_CR14","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/S0140-6736(77)92496-5","volume":"2","author":"A Bennett","year":"1977","unstructured":"Bennett A, McDonald A, Stamford I, Charlier E, Simpson J, Zebro T. Prostaglandins and breast cancer. Lancet. 1977;2(8039):624\u20136.","journal-title":"Lancet."},{"issue":"1","key":"1135_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.steroids.2007.09.011","volume":"73","author":"B Su","year":"2008","unstructured":"Su B, D\u00edaz-Cruz ES, Landini S, Brueggemeier RW. Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids. 2008;73(1):104\u201311.","journal-title":"Steroids."},{"issue":"3","key":"1135_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/heart.85.3.265","volume":"85","author":"PS Sanmuganathan","year":"2001","unstructured":"Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001;85(3):265\u201371.","journal-title":"Heart."},{"issue":"7270","key":"1135_CR17","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/bmj.321.7270.1183","volume":"321","author":"S Derry","year":"2000","unstructured":"Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321(7270):1183\u20137.","journal-title":"BMJ."},{"issue":"11","key":"1135_CR18","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"RS Bresalier","year":"2005","unstructured":"Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092\u2013102.","journal-title":"N Engl J Med"},{"issue":"21","key":"1135_CR19","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343(21):1520\u20138.","journal-title":"N Engl J Med"},{"key":"1135_CR20","volume-title":"FDA briefing document on nonsteroidal anti-inflammatory drugs and cardiovascular thrombotic risk. Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management, Advisory Committee, April","author":"US Food and Drug Administration","year":"2018","unstructured":"US Food and Drug Administration. FDA briefing document on nonsteroidal anti-inflammatory drugs and cardiovascular thrombotic risk. Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management, Advisory Committee, April, vol. 24-25; 2018. \n                    https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ArthritisAdvisoryCommittee\/UCM605207.pdf\n                    \n                  . Accessed August 8, 2018"},{"issue":"16","key":"1135_CR21","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","volume":"379","author":"John J. McNeil","year":"2018","unstructured":"McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1803955\n                    \n                  .","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"1135_CR22","doi-asserted-by":"publisher","first-page":"376","DOI":"10.7326\/0003-4819-146-5-200703060-00010","volume":"146","author":"A Rostom","year":"2007","unstructured":"Rostom A, Dub\u00e9 C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Intern Med. 2007;146(5):376\u201389.","journal-title":"Ann Intern Med"},{"issue":"9754","key":"1135_CR23","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","volume":"376","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM, Wilson M, Elwin C-E, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741\u201350.","journal-title":"Lancet."},{"issue":"2","key":"1135_CR24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10549-011-1747-0","volume":"131","author":"T Luo","year":"2012","unstructured":"Luo T, Yan H-M, He P, Luo Y, Yang Y-F, Zheng H. Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2012;131(2):581\u20137.","journal-title":"Breast Cancer Res Treat"},{"issue":"25","key":"1135_CR25","doi-asserted-by":"crossref","first-page":"40389","DOI":"10.18632\/oncotarget.16315","volume":"8","author":"L Lu","year":"2017","unstructured":"Lu L, Shi L, Zeng J, Wen Z. Aspirin as a potential modality for the chemoprevention of breast cancer: a dose-response meta-analysis of cohort studies from 857,831 participants. Oncotarget. 2017;8(25):40389\u2013401.","journal-title":"Oncotarget."},{"issue":"2","key":"1135_CR26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10549-015-3267-9","volume":"149","author":"M de Pedro","year":"2015","unstructured":"de Pedro M, Baeza S, Escudero M-T, et al. Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2015;149(2):525\u201336.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1135_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/pds.983","volume":"14","author":"R Paulose-Ram","year":"2005","unstructured":"Paulose-Ram R, Hirsch R, Dillon C, Gu Q. Frequent monthly use of selected non-prescription and prescription non-narcotic analgesics among US adults. Pharmacoepidemiol Drug Saf. 2005;14(4):257\u201366.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"1135_CR28","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1158\/1055-9965.EPI-15-0452","volume":"24","author":"S Zhong","year":"2015","unstructured":"Zhong S, Chen L, Zhang X, Yu D, Tang J, Zhao J. Aspirin use and risk of breast cancer: systematic review and meta-analysis of observational studies. Cancer Epidemiol Biomark Prev. 2015;24(11):1645\u201355.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"1","key":"1135_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jama.294.1.47","volume":"294","author":"NR Cook","year":"2005","unstructured":"Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294(1):47\u201355.","journal-title":"JAMA."},{"issue":"36","key":"1135_CR30","doi-asserted-by":"publisher","first-page":"TPS597","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS597","volume":"15_suppl","author":"WY Chen","year":"2018","unstructured":"Chen WY, Winer EP, Barry WT, et al. ABC trial (A011502): randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for breast cancer. J Clin Oncol. 2018;15_suppl(36):TPS597.","journal-title":"J Clin Oncol"},{"key":"1135_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cct.2016.10.004","volume":"51","author":"C Coyle","year":"2016","unstructured":"Coyle C, Cafferty FH, Rowley S, et al. ADD-ASPIRIN: a phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemp Clin Trials. 2016;51:56\u201364.","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"1135_CR32","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1186\/s12885-015-1979-1","volume":"15","author":"S Kim","year":"2015","unstructured":"Kim S, Shore DL, Wilson LE, et al. Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer. BMC Cancer. 2015;15(1):960.","journal-title":"BMC Cancer"},{"issue":"2","key":"1135_CR33","first-page":"1","volume":"8","author":"JL Hopper","year":"2011","unstructured":"Hopper JL. Disease-specific prospective family study cohorts enriched for familial risk. Epidemiol Perspect Innov. 2011;8(2):1\u20139.","journal-title":"Epidemiol Perspect Innov"},{"issue":"3","key":"1135_CR34","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/ije\/dyv118","volume":"45","author":"MB Terry","year":"2015","unstructured":"Terry MB, Phillips KA, Daly MB, et al. Cohort profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC). Int J Epidemiol. 2015;45(3):683\u201392.","journal-title":"Int J Epidemiol"},{"issue":"8","key":"1135_CR35","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/sj.bjc.6602175","volume":"91","author":"A Antoniou","year":"2004","unstructured":"Antoniou A, Pharoah P, Smith P, Easton D. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer. 2004;91(8):1580\u201390.","journal-title":"Br J Cancer"},{"issue":"8","key":"1135_CR36","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/sj.bjc.6604305","volume":"98","author":"AC Antoniou","year":"2008","unstructured":"Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 2008;98(8):1457\u201366.","journal-title":"Br J Cancer"},{"issue":"5","key":"1135_CR37","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/bjc.2013.382","volume":"109","author":"R MacInnis","year":"2013","unstructured":"MacInnis R, Bickerstaffe A, Apicella C, et al. Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre. Br J Cancer. 2013;109(5):1296\u2013301.","journal-title":"Br J Cancer"},{"issue":"4","key":"1135_CR38","doi-asserted-by":"publisher","first-page":"R375","DOI":"10.1186\/bcr801","volume":"6","author":"EM John","year":"2004","unstructured":"John EM, Hopper JL, Beck JC, et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res. 2004;6(4):R375\u201389.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1135_CR39","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/bcr1377","volume":"8","author":"GJ Mann","year":"2006","unstructured":"Mann GJ, Thorne H, Balleine RL, et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res. 2006;8(1):R12.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"1135_CR40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10549-008-0153-8","volume":"116","author":"SL Neuhausen","year":"2009","unstructured":"Neuhausen SL, Ozcelik H, Southey MC, et al. BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research. Breast cancer research and treatment. Breast Cancer Res Treat. 2009;116(2):379\u201386.","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"1135_CR41","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1001\/jama.291.20.2433","volume":"291","author":"MB Terry","year":"2004","unstructured":"Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 2004;291(20):2433\u201340.","journal-title":"JAMA."},{"key":"1135_CR42","unstructured":"Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2011 Sub (1973\u20132009) <Katrina\/Rita Population Adjustment> \u2212 Linked To County Attributes - Total U.S.; 2011."},{"key":"1135_CR43","unstructured":"Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 13 Regs Research Data, Nov 2011 Sub (1992\u20132009) <Katrina\/Rita Population Adjustment> \u2212 Linked To County Attributes - Total U.S.; 2011."},{"key":"1135_CR44","unstructured":"Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 18 Regs Research Data, Nov 2011 Sub (2000\u20132009) <Katrina\/Rita Population Adjustment> \u2212 Linked To County Attributes - Total U.S.; 2011."},{"issue":"1","key":"1135_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/gepi.20074","volume":"29","author":"AC Antoniou","year":"2005","unstructured":"Antoniou AC, Goldgar DE, Andrieu N, et al. A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol. 2005;29(1):1\u201311.","journal-title":"Genet Epidemiol"},{"key":"1135_CR46","volume-title":"Stata statistical software: release 15","author":"StataCorp","year":"2017","unstructured":"StataCorp. Stata statistical software: release 15. College Station, TX: StataCorp LLC; 2017."},{"issue":"11","key":"1135_CR47","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/jnci\/dji140","volume":"97","author":"SF Marshall","year":"2005","unstructured":"Marshall SF, Bernstein L, Anton-Culver H, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst. 2005;97(11):805\u201312.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1135_CR48","doi-asserted-by":"publisher","first-page":"R38","DOI":"10.1186\/bcr2089","volume":"10","author":"GL Gierach","year":"2008","unstructured":"Gierach GL, Lacey JV, Schatzkin A, et al. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health\u2013AARP Diet and Health Study. Breast Cancer Res. 2008;10(2):R38.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1135_CR49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10549-010-1074-x","volume":"126","author":"A Bardia","year":"2011","unstructured":"Bardia A, Olson JE, Vachon CM, et al. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat. 2011;126(1):149\u201355.","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"1135_CR50","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1002\/cncr.21763","volume":"106","author":"L Gallicchio","year":"2006","unstructured":"Gallicchio L, McSorley MA, Newschaffer CJ, et al. Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer. 2006;106(7):1443\u201352.","journal-title":"Cancer."},{"issue":"17","key":"1135_CR51","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1056\/NEJMoa1207756","volume":"367","author":"X Liao","year":"2012","unstructured":"Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596\u2013606.","journal-title":"N Engl J Med"},{"issue":"10","key":"1135_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2013.91","volume":"45","author":"B-H Choi","year":"2013","unstructured":"Choi B-H, Chakraborty G, Baek K, Yoon HS. Aspirin-induced Bcl-2 translocation and its phosphorylation in the nucleus trigger apoptosis in breast cancer cells. Exp Mol Med. 2013;45(10):e47.","journal-title":"Exp Mol Med"},{"issue":"1","key":"1135_CR53","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/1471-2407-14-141","volume":"14","author":"L Huang","year":"2014","unstructured":"Huang L, Wong CC, Mackenzie GG, et al. Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress. BMC Cancer. 2014;14(1):141.","journal-title":"BMC Cancer"},{"issue":"12","key":"1135_CR54","doi-asserted-by":"publisher","first-page":"836","DOI":"10.7326\/M16-0577","volume":"164","author":"K Bibbins-Domingo","year":"2016","unstructured":"Bibbins-Domingo K. US Preventive Services Task Force. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164(12):836\u201345.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1135_CR55","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/pds.3463","volume":"23","author":"Y Zhou","year":"2014","unstructured":"Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general US population. Pharmacoepidemiol Drug Saf. 2014;23(1):43\u201350.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1135_CR56","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/FPC.0000000000000113","volume":"25","author":"LL Mazaleuskaya","year":"2015","unstructured":"Mazaleuskaya LL, Theken KN, Gong L, et al. PharmGKB summary: ibuprofen pathways. Pharmacogenet Genomics. 2015;25(2):96\u2013106.","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"1135_CR57","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/pds.1864","volume":"19","author":"M Hargreave","year":"2010","unstructured":"Hargreave M, Andersen TV, Nielsen A, Munk C, Liaw KL, Kjaer SK. Factors associated with a continuous regular analgesic use\u2014a population-based study of more than 45 000 Danish women and men 18\u201345 years of age. Pharmacoepidemiol Drug Saf. 2010;19(1):65\u201374.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-019-1135-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-019-1135-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-019-1135-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T13:12:10Z","timestamp":1589548330000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-019-1135-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,18]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1135"],"URL":"https:\/\/doi.org\/10.1186\/s13058-019-1135-y","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,18]]},"assertion":[{"value":"20 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants in the BCFR and kConFab provided written informed consent before participation. Human research ethics committees at the participating institutions granted ethics approval for the six sites of the BCFR and for kConFab:Northern California\u2014Cancer Prevention Institute of California, Institutional Review Board (2001\u2013033) and Stanford University School of Medicine, Institutional Review Board (45842).New York\u2014Columbia University Medical Center, Institutional Review Board (AAA7794).Philadelphia\u2014Fox Chase Cancer Center, Institutional Review Board (95\u2013009).Utah\u2014Huntsman Cancer Institute, University of Utah, Institutional Review Board (00004965).Ontario\u2014Mount Sinai Hospital Research Ethics Board (#02\u20130076-U) and University Health Network Research Ethics Board (#96-U107-CE).Australia\u2014University of Melbourne, Human Ethics Sub-Committee (1441420.1).kConFab\u2014Peter MacCallum Cancer Centre, the Peter Mac Ethics Committee (97\/27).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"52"}}